ライフサイエンスコーパス: cyclic guanosine monophosphate

1 ors increase intracellular concentrations of cyclic guanosine monophosphate.

2 ed and stiff because of low nitric oxide and cyclic guanosine monophosphate.

3 denosine monophosphate [8br-cAMP] and 8bromo cyclic guanosine monophosphate [8br-cGMP]) in rat liver

4 n, 8-bromo-cyclic AMP (8BrcAMP), and 8-bromo-cyclic guanosine monophosphate (8BrcGMP) also inhibited

5 effect of sGCalpha1 is independent of NO and cyclic guanosine monophosphate, a major mediator of the

6 Urinary excretion of cyclic guanosine monophosphate, a marker for renal NO pr

7 Tissue 3',5'-cyclic guanosine monophosphate, a potent vasodilator, wa

8 oth basal and bradykinin-stimulated cellular cyclic guanosine monophosphate accumulation and L-citrul

9 e presence or absence of 7-nitroindazole and cyclic guanosine monophosphate accumulation was determin

10 o determined in vitro in cardiac fibroblasts cyclic guanosine monophosphate-activating and antiprolif

11 mune checkpoint by hydrolyzing extracellular cyclic guanosine monophosphate adenosine monophosphate (

12 (CDN), mimicked the endogenous STING ligand cyclic guanosine monophosphate adenosine monophosphate,

13 PS)-biomimetic liposomes encapsulating 2',3'-cyclic guanosine monophosphate-adenosine monophosphate (

14 Here we show that cytoplasmic sensor cyclic guanosine monophosphate-adenosine monophosphate (

15 ne coated liposome loaded with STING agonist cyclic guanosine monophosphate-adenosine monophosphate (

16 Cyclic guanosine monophosphate-adenosine monophosphate (

17 latform using nanocomplexes composed of 2'3'-cyclic guanosine monophosphate-adenosine monophosphate (

18 nation polymer (NCP), oxaliplatin (OX)/2',3'-cyclic guanosine monophosphate-adenosine monophosphate (

19 Here, we use a CDN, 2'3' cyclic guanosine monophosphate-adenosine monophosphate (

20 d when combined with the STING agonist 2',3'-cyclic guanosine monophosphate-adenosine monophosphate (

21 ding to the synthesis of a second messenger, cyclic guanosine monophosphate-adenosine monophosphate (

22 ions and mounted an antitumor response after cyclic guanosine monophosphate-adenosine monophosphate (

23 The activation of STING in CD4+ T cells by cyclic guanosine monophosphate-adenosine monophosphate (

24 result in production of the second messenger cyclic guanosine monophosphate-adenosine monophosphate (

25 of the endogenous CDN ligand for STING, 2'3' cyclic guanosine monophosphate-adenosine monophosphate (

26 The DNA sensor cyclic guanosine monophosphate-adenosine monophosphate (

27 timulator of interferon genes (STING), 2'3'- cyclic guanosine monophosphate-adenosine monophosphate (

28 chromatin without linker histone stimulates cyclic guanosine monophosphate-adenosine monophosphate (

29 Here we show that M. tuberculosis activated cyclic guanosine monophosphate-adenosine monophosphate (

30 With the STING ligand cyclic guanosine monophosphate-adenosine monophosphate (

31 Here we show that HIV infection activates cyclic guanosine monophosphate-adenosine monophosphate (

32 ical approaches led to the identification of cyclic guanosine monophosphate-adenosine monophosphate (

33 nduces interferons through the production of cyclic guanosine monophosphate-adenosine monophosphate (

34 e revealed that SR-717 functions as a direct cyclic guanosine monophosphate-adenosine monophosphate (

35 hat mammalian cytosolic extracts synthesized cyclic guanosine monophosphate-adenosine monophosphate (

36 2'3'-cyclic guanosine monophosphate-adenosine monophosphate (

37 f in vitro release of dexamethasone and 3'3'-cyclic guanosine monophosphate-adenosine monophosphate f

38 observed an altered distribution of nuclear cyclic guanosine monophosphate-adenosine monophosphate s

39 The cyclic guanosine monophosphate-adenosine monophosphate s

40 MYND8 triggered activation of the DNA sensor cyclic guanosine monophosphate-adenosine monophosphate s

41 Activation of the cyclic guanosine monophosphate-adenosine monophosphate s

42 Cyclic guanosine monophosphate-adenosine monophosphate s

43 ust phagocytosis and activates the phagocyte cyclic guanosine monophosphate-adenosine monophosphate s

44 d protein directly suppresses DNA sensing by cyclic guanosine monophosphate-adenosine monophosphate s

45 ndrial homeostasis and the activation of the cyclic guanosine monophosphate-adenosine monophosphate s

46 e used to dissect the molecular mechanism of cyclic guanosine monophosphate-adenosine monophosphate s

47 MYND8 triggered activation of the DNA sensor cyclic guanosine monophosphate-adenosine monophosphate s

48 llular DNA-sensing pathways (cGAS-STING (for cyclic guanosine monophosphate-adenosine monophosphate s

49 hrough a pathway dependent on the DNA sensor cyclic guanosine monophosphate-adenosine monophosphate s

50 A or HBV infection and mice lacking STING or cyclic guanosine monophosphate-adenosine monophosphate s

51 Cyclic guanosine monophosphate-adenosine monophosphate s

52 DmPAC and a derivative for 3', 5'-cyclic guanosine monophosphate allow the manipulation of

53 increased levels of interferon response in a cyclic guanosine monophosphate-AMP (cGAMP) synthase (cGA

54 gnals downstream of the cytosolic DNA sensor cyclic guanosine monophosphate-AMP synthase (cGAS), lead

55 poptosis, and these effects were mimicked by cyclic guanosine monophosphate analogs.

56 biological pathway, such as the nitric oxide-cyclic guanosine monophosphate and endothelin pathways (

57 In addition, CD-NP in vitro activates cyclic guanosine monophosphate and inhibits cardiac fibr

58 lation of cyclic adenosine monophosphate and cyclic guanosine monophosphate and is highly expressed i

59 oxide synthase (NOS) activity and decreased cyclic guanosine monophosphate and nitrite production.

60 Venous admixture was calculated, and plasma cyclic guanosine monophosphate and sildenafil concentrat

61 s associated with elevation of intraplatelet cyclic guanosine monophosphate and was reversed by the n

62 itric oxide-dependent signaling (via sGC and cyclic guanosine monophosphate) and nitric oxide-indepen

63 levels of cyclic adenosine monophosphate and cyclic guanosine monophosphate, and, consequently, exhib

64 eases in vascular endothelial growth factor, cyclic guanosine monophosphate, angiogenesis, endogenous

65 nhardtii indicates that NO signaling through cyclic guanosine monophosphate arose before the origin o

66 aptic activity, acetylcholine, nitric oxide, cyclic guanosine monophosphate, ATP-sensitive potassium

67 sists of drugs that enhance the nitric oxide-cyclic guanosine monophosphate biological pathway (silde

68 aggregation in vitro by preventing platelet cyclic guanosine monophosphate catabolism.

69 n of hypotensive mediators, nitric oxide and cyclic guanosine monophosphate, cause these phenotypes.

70 In vitro 3',5'-cyclic guanosine monophosphate (cGMP) activation in resp

71 Sildenafil and an analog of cyclic guanosine monophosphate (cGMP) also induced capil

72 f IkappaBalpha accumulation; and b) a stable cyclic guanosine monophosphate (cGMP) analog (8-bromo-cG

73 sterase 3B (PDE3B), and a membrane-permeable cyclic guanosine monophosphate (cGMP) analog on KATP cha

74 Type V phosphodiesterase (PDE V) metabolizes cyclic guanosine monophosphate (cGMP) and is abundant in

75 In healthy control subjects, urinary cyclic guanosine monophosphate (cGMP) and natriuresis in

76 NP (ANP) and significantly smaller levels of cyclic guanosine monophosphate (cGMP) and peroxisome pro

77 sterase 5 (PDE5) catalytic-site affinity for cyclic guanosine monophosphate (cGMP) and potency of inh

78 iesterase type 5 (PDE5) acts specifically on cyclic guanosine monophosphate (cGMP) and terminates cGM

79 In this study we tested the hypothesis that cyclic guanosine monophosphate (cGMP) and the dependent

80 T-cyclic guanosine monophosphate (RpcGMP), a cyclic guanosine monophosphate (cGMP) antagonist, attenu

81 G protein-coupled receptors and cyclic guanosine monophosphate (cGMP) are implicated in

82 Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are now recognized

83 provided evidence that nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) are signaling inte

84 production by using immunocytochemistry for cyclic guanosine monophosphate (cGMP) as an indicator.

85 de cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) as well as calcium

86 Agents that raise cyclic guanosine monophosphate (cGMP) by activating prot

87 Production of cyclic guanosine monophosphate (cGMP) by guanylate cycla

88 coronary vasodilation through activation of cyclic guanosine monophosphate (cGMP) by way of particul

89 resistance may, in part, relate to increased cyclic guanosine monophosphate (cGMP) catabolism by PDE5

90 scular NO production, as estimated by aortic cyclic guanosine monophosphate (cGMP) concentration and

91 morphism in dogs that results in lower basal cyclic guanosine monophosphate (cGMP) concentrations tha

92 Atrial and serum nitrite/ nitrate and atrial cyclic guanosine monophosphate (cGMP) concentrations wer

93 Cyclic guanosine monophosphate (cGMP) content in the cha

94 y, nitric oxide synthase (NOS) activity, and cyclic guanosine monophosphate (cGMP) content were also

95 Moreover, relaxation was cyclic guanosine monophosphate (cGMP) dependent and was

96 , we hypothesized that nitric oxide promotes cyclic guanosine monophosphate (cGMP) formation, which,

97 , which stimulates production and release of cyclic guanosine monophosphate (cGMP) from intestinal ep

98 have determined that at least 6 TAX-2/TAX-4 cyclic guanosine monophosphate (cGMP) gated channel expr

99 as associated with a significant decrease in cyclic guanosine monophosphate (cGMP) generation after S

100 ent production of the second messenger 3',5'-cyclic guanosine monophosphate (cGMP) have been shown to

101 ssociating from the membrane, metabolites of cyclic guanosine monophosphate (cGMP) hydrolysis, or by-

102 nding strength and fluorescence response for cyclic guanosine monophosphate (cGMP) in an aqueous solu

103 production of NO, as estimated by measuring cyclic guanosine monophosphate (cGMP) in aortic tissue i

104 peptide (BNP) on cellular proliferation and cyclic guanosine monophosphate (cGMP) in human aortic va

105 PDE9-I dose-dependently increased plasma cyclic guanosine monophosphate (cGMP) in normal sheep (p

106 (5-HT(2A)) receptors increase production of cyclic guanosine monophosphate (cGMP) in slices of rat f

107 tical slices obtained from endotoxemic mice, cyclic guanosine monophosphate (cGMP) increased signific

108 d by nitrite and nitrate accumulation and by cyclic guanosine monophosphate (cGMP) increases in rat r

109 3',5'-cyclic guanosine monophosphate (cGMP) is a common second

110 Cyclic guanosine monophosphate (cGMP) is a key secondary

111 Cyclic guanosine monophosphate (cGMP) is a second messen

112 Cyclic guanosine monophosphate (cGMP) is an important in

113 3',5'-Cyclic guanosine monophosphate (cGMP) is an important se

114 The intracellular nucleotide cyclic guanosine monophosphate (cGMP) is found in many h

115 te (cAMP) - very surprising considering that cyclic guanosine monophosphate (cGMP) is used in almost

116 ase (sGC) production of the second messenger cyclic guanosine monophosphate (cGMP) leading to increas

117 Phosphodiesterase 5 (PDE5) hydrolyzes cyclic guanosine monophosphate (cGMP) leading to increas

118 n = 5) and 28 days (n = 3) and evaluated for cyclic guanosine monophosphate (cGMP) levels (7 days), n

119 itor with a short half-life, increases brain cyclic guanosine monophosphate (cGMP) levels and improve

120 e messenger RNA (mRNA), protein, nitrite and cyclic guanosine monophosphate (cGMP) levels in Kupffer

121 sion/4-minute reperfusion cycles, myocardial cyclic guanosine monophosphate (cGMP) levels increased s

122 Vascular cyclic guanosine monophosphate (cGMP) levels were elevat

123 sulin with and without SNP did not affect EC cyclic guanosine monophosphate (cGMP) levels, and the cG

124 HO2 phosphorylation and activity as well as cyclic guanosine monophosphate (cGMP) levels, with all o

125 soluble guanylyl cyclase and, thus, enhances cyclic guanosine monophosphate (cGMP) levels.

126 Elevated intracellular levels of cyclic guanosine monophosphate (cGMP) may induce apoptos

127 partly attributable to hyporesponsiveness of cyclic guanosine monophosphate (cGMP) mediated vasorelax

128 In the vertebrate retina, cyclic guanosine monophosphate (cGMP) mediates photorece

129 ic cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) often mediate anta

130 enzyme producing the intracellular messenger cyclic guanosine monophosphate (cGMP) on activation with

131 activates the kinase independently of the NO-cyclic guanosine monophosphate (cGMP) pathway and is cou

132 mammals, the diatomic gas is critical to the cyclic guanosine monophosphate (cGMP) pathway as it func

133 rturbation of the atrial natriuretic peptide-cyclic guanosine monophosphate (cGMP) pathway in cardiac

134 A key component of the nitric oxide-cyclic guanosine monophosphate (cGMP) pathway in smooth

135 O activates a soluble guanylyl cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway in the beh

136 O-sensitive (soluble) guanylyl cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway regulates

137 sodilator tone and platelet activity via the cyclic guanosine monophosphate (cGMP) pathway, but wheth

138 gulation of intracellular Ca2+ ([Ca2+]i) and cyclic guanosine monophosphate (cGMP) production (index

139 ignaling in biology relies on its activating cyclic guanosine monophosphate (cGMP) production by the

140 rrent study was to determine whether hepatic cyclic guanosine monophosphate (cGMP) reduces NHGU.

141 channels and, thereby, adjusts the channel's Cyclic guanosine monophosphate (cGMP) sensitivity in res

142 Recent clinical trials of drugs enhancing cyclic guanosine monophosphate (cGMP) signaling for card

143 ion of NP (natriuretic peptide) receptor and cyclic guanosine monophosphate (cGMP) signaling has emer

144 ape and provide evidence for a novel role of cyclic guanosine monophosphate (cGMP) signaling in the r

145 adenosine monophosphate (cAMP) and augmented cyclic guanosine monophosphate (cGMP) signaling is chara

146 (PKGs) are key mediators of the nitric oxide/cyclic guanosine monophosphate (cGMP) signaling pathway

147 The cyclic guanosine monophosphate (cGMP) specific phosphodi

148 Cyclic guanosine monophosphate (cGMP) stimulated human p

149 ic measurement of [Ca (2+)] i in response to cyclic guanosine monophosphate (cGMP) stimulation.

150 ependent on and independent of modulation of cyclic guanosine monophosphate (cGMP) subsequent to acti

151 A class of agonists can activate cyclic guanosine monophosphate (cGMP) synthesis by forms

152 Assays of cyclic guanosine monophosphate (cGMP) synthesis from gua

153 he phosphodiesterase PDE1A, which hydrolyzed cyclic guanosine monophosphate (cGMP) to decrease the cG

154 cAMP) was increased 11-fold and the K(i) for cyclic guanosine monophosphate (cGMP) was 27-fold higher

155 Cyclic guanosine monophosphate (cGMP) was measured by en

156 y investigated whether nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) were involved in m

157 itric oxide (NO), catalyzes the formation of cyclic guanosine monophosphate (cGMP), an intracellular

158 thase expression and levels of nitric oxide, cyclic guanosine monophosphate (cGMP), and nitrotyrosine

159 chemical methods to study the effects of NO, cyclic guanosine monophosphate (cGMP), and peroxynitrite

160 ften functions through its second messenger, cyclic guanosine monophosphate (cGMP), and protein kinas

161 tivates soluble guanosine cyclase to produce cyclic guanosine monophosphate (cGMP), and we observed t

162 f the nitric oxide pathway effector molecule cyclic guanosine monophosphate (cGMP), has been implicat

163 Cyclic guanosine monophosphate (cGMP), however, has been

164 es cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is preferentially

165 The second messenger, cyclic guanosine monophosphate (cGMP), mediates the acti

166 NO-mediated events, such as the induction of cyclic guanosine monophosphate (cGMP), NADPH diaphorase

167 yocyte diameter, and its upstream control by cyclic guanosine monophosphate (cGMP), nitrosative/oxida

168 Inhibitors and activators of sGC, 3',5'-cyclic guanosine monophosphate (cGMP), protein kinase G

169 lic adenosine monophosphate (cAMP) and 3',5'-cyclic guanosine monophosphate (cGMP), which are second

170 yclase in follicular somatic cells, produces cyclic guanosine monophosphate (cGMP), which maintains m

171 t report, VWF did not promote an increase in cyclic guanosine monophosphate (cGMP), while agents that

172 is a downstream target of sildenafil in the cyclic guanosine monophosphate (cGMP)-activated protein

173 d channel from Caenorhabditis elegans in the cyclic guanosine monophosphate (cGMP)-bound open state.

174 y depends on NOS2 activity and the canonical cyclic guanosine monophosphate (cGMP)-cGMP-dependent pro

175 The gene Prkg2, encoding cyclic guanosine monophosphate (cGMP)-dependent protein

176 Cyclic guanosine monophosphate (cGMP)-dependent protein

177 filaments are phosphorylated transiently by cyclic guanosine monophosphate (cGMP)-dependent protein

178 pecies is the foraging gene, which encodes a cyclic guanosine monophosphate (cGMP)-dependent protein

179 s as a signalling paradigm, we show that the cyclic guanosine monophosphate (cGMP)-dependent protein

180 ns, whereas the response to ascr#3 relies on cyclic guanosine monophosphate (cGMP)-gated channels and

181 Mutations in genes encoding subunits of a cyclic guanosine monophosphate (cGMP)-gated ion channel

182 both endothelium-dependent and -independent cyclic guanosine monophosphate (cGMP)-mediated vasodilat

183 e from an intrinsic random activation of the cyclic guanosine monophosphate (cGMP)-phosphodiesterase

184 voking a depolarizing conductance carried by cyclic guanosine monophosphate (cGMP)-sensitive cyclic n

185 shed leukocyte Mac-1-integrin activation and cyclic guanosine monophosphate (cGMP)-signaling, leading

186 n that converts guanosine-5'-triphosphate to cyclic guanosine monophosphate (cGMP).

187 d decreasing intracellular concentrations of cyclic guanosine monophosphate (cGMP).

188 neurons label positively with an antibody to cyclic guanosine monophosphate (cGMP).

189 ate nitric oxide (NO) and increase levels of cyclic guanosine monophosphate (cGMP).

190 n by increasing pulmonary vascular levels of cyclic guanosine monophosphate (cGMP).

191 ng cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP).

192 rough the generation of its second messenger cyclic guanosine monophosphate (cGMP).

193 s are homodimers that generate intracellular cyclic guanosine monophosphate (cGMP).

194 r-guanylyl-cyclase, GCY-8, which synthesizes cyclic guanosine monophosphate (cGMP).

195 of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP).

196 nhibition of calcium influx into the cell by cyclic guanosine monophosphate (cGMP).

197 f the muscle to the relaxant effects of 8-Br-cyclic guanosine monophosphate (cGMP).

198 resulted in markedly increased production of cyclic guanosine monophosphate (cGMP).

199 The elevated cyclic guanosine monophosphate (cGMP)/cGMP-dependent pro

200 e proliferative effect is mediated via an NO/cyclic guanosine monophosphate (cGMP)/cGMP-dependent pro

201 he major PDE activity in platelets is PDE3A (cyclic guanosine monophosphate [cGMP]-inhibited PDE).

202 gh soluble guanylyl cyclase (which generates cyclic guanosine monophosphate, cGMP) was the first iden

203 By using immunohistochemistry against cyclic guanosine monophosphate, cochlear sGC activity wa

204 CI: -3.97%, -0.61%; P = 0.04) and attenuated cyclic guanosine monophosphate concentrations.

205 ity by inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content by neprilysin or

206 mation reduces nitric oxide bioavailability, cyclic guanosine monophosphate content, and protein kina

207 cGMP (B-cGMP) and N(2),2'-o-dibutyryl 3', 5'-cyclic guanosine monophosphate (dB-cGMP), and of the sel

208 by its endogenous peptide ligands initiates cyclic guanosine monophosphate-dependent (cGMP) salt and

209 f cell cycle progression, which include both cyclic guanosine monophosphate-dependent and -independen

210 ing proteins involved in the mating process, cyclic guanosine monophosphate-dependent kinase, and the

211 PT1 in vessels from endotoxemic animals in a cyclic guanosine monophosphate-dependent manner, suggest

212 The arrest was downstream of cyclic guanosine monophosphate-dependent protein kinase

213 ion of either guanylyl cyclase A receptor or cyclic guanosine monophosphate-dependent protein kinase

214 racellular signal-related kinase pathway via cyclic guanosine monophosphate-dependent protein kinase

215 ositol 4-kinase type III beta (PI4Kbeta) and cyclic guanosine monophosphate-dependent protein kinase

216 synthetase, N-myristoyltransferase, and the cyclic guanosine monophosphate-dependent protein kinase

217 atriuresis associated with increased urinary cyclic guanosine monophosphate excretion (UcGMPV), glome

218 gh glucose media was paralleled by decreased cyclic guanosine monophosphate generation; however, ther

219 s that catalyze the breakdown of cAMP and/or cyclic guanosine monophosphate (GMP) to their inactive f

220 that triggers the innate immune response is cyclic guanosine monophosphate (GMP)-adenosine monophosp

221 The cyclic guanosine monophosphate (GMP)-adenosine monophosp

222 Cyclic guanosine monophosphate (GMP)-adenosine monophosp

223 ystal structure of Acb4 in complex with 3'3'-cyclic guanosine monophosphate (GMP)-AMP (3'3'-cGAMP) re

224 x and amplified tauopathy-induced microglial cyclic guanosine monophosphate (GMP)-AMP synthase (cGAS)

225 The cyclic guanosine monophosphate (GMP)-AMP synthase (cGAS)

226 owed competitive inhibition with cytoplasmic cyclic guanosine monophosphate (GMP)-AMP synthase (CGAS)

227 hrough the recognition of cytosolic mtDNA by cyclic guanosine monophosphate (GMP)-AMP synthase (cGAS)

228 ally increased in parallel with a decline in cyclic guanosine monophosphate (GMP).

229 Other strategies to increase tissue cyclic guanosine monophosphate have been attempted, such

230 Most cyclic guanosine monophosphate hydrolysis (about 80%) in

231 Sildenafil is a potent inhibitor of cyclic guanosine monophosphate hydrolysis [corrected] in

232 sterase Type 5 is the main factor regulating cyclic guanosine monophosphate hydrolysis and downstream

233 d to exogenous NO also was examined by using cyclic guanosine monophosphate immunocytochemistry.

234 l-specificity cyclic adenosine monophosphate/cyclic guanosine monophosphate-inhibiting enzyme.

235 Cyclic guanosine monophosphate is mainly hydrolyzed by P

236 ble ST2, atrial natriuretic peptide, urinary cyclic guanosine monophosphate), Kansas City Cardiomyopa

237 clin expression was accompanied by decreased cyclic guanosine monophosphate levels and PGC-1alpha exp

238 induced a greater elevation of intracellular cyclic guanosine monophosphate levels compared with nitr

239 Reduced cyclic guanosine monophosphate levels contribute to HF p

240 Modulating cyclic guanosine monophosphate levels within the natriur

241 n, ventricles from Cav-3 OE mice had greater cyclic guanosine monophosphate levels, less nuclear fact

242 Neither cyclic guanosine monophosphate nor guanylate cyclase wer

243 creased NO-stimulated platelet generation of cyclic guanosine monophosphate (p < 0.02) but not with c

244 as was the ability to activate plasma 3',5'-cyclic guanosine monophosphate (p < 0.05 vs. placebo).

245 normalized ex vivo by augmentation of the NO-cyclic guanosine monophosphate pathway without normaliza

246 evels, which they detect through a rhodopsin-cyclic guanosine monophosphate pathway.

247 Mechanisms of action of nitric oxide/cyclic guanosine monophosphate/PDE5 pathway in the treat

248 utant allele of the gamma subunit of retinal cyclic guanosine monophosphate phosphodiesterase (PDE ga

249 ctive toward the effector of transducin, the cyclic guanosine monophosphate phosphodiesterase.

250 splice site mutation in intron 2 of the rod cyclic guanosine monophosphate-phosphodiesterase (cGMP)

251 photoreceptor-specific expression of the rod cyclic guanosine monophosphate-phosphodiesterase beta-su

252 ted extracellular matrix remodeling via PDE5/cyclic guanosine monophosphate-PKG regulatory pathways.

253 ENO-treated kidneys had higher levels of cyclic guanosine monophosphate, potentially explaining t

254 alogue RO-25-6760, increased NPR-A-dependent cyclic guanosine monophosphate production and NPR-A gene

255 variant in reporter cells resulted in higher cyclic guanosine monophosphate production compared with

256 ly available BNP assays and cell activity by cyclic guanosine monophosphate production in vascular ce

257 nd nitric oxide synthase 1 blockade inhibits cyclic guanosine monophosphate production; 3) pharmacolo

258 complex pathways that involve nitric oxide, cyclic guanosine monophosphate, protein kinase G, extrac

259 gents induce vasodilatation via nitric oxide-cyclic guanosine monophosphate-protein kinase G (i.e. NO

260 jor downstream effectors in the nitric oxide-cyclic guanosine monophosphate-protein kinase G (i.e. NO

261 Low myocardial cGMP-PKG (cyclic guanosine monophosphate-protein kinase G) activit

262 the canonical pathway guanylyl cyclase/3',5'-cyclic guanosine monophosphate/protein kinase G.

263 Plasma BNP and 3',5'-cyclic guanosine monophosphate rapidly increased and pea

264 itric oxide synthase inhibitor, and Rp-8 CPT-cyclic guanosine monophosphate (RpcGMP), a cyclic guanos

265 l, gene-targeted regulation of cardiomyocyte cyclic guanosine monophosphate-selective phosphodiestera

266 Phosphodiesterase-5 inhibitors and other cyclic guanosine monophosphate signaling activators work

267 Combined treatment with N-acetylcysteine and cyclic guanosine monophosphate signaling enhancers warra

268 Abnormal cyclic guanosine monophosphate signaling may contribute

269 Sildenafil (SIL) inhibits cyclic guanosine monophosphate-specific PDE5A and can bl

270 guanylate cyclase and a higher production of cyclic guanosine monophosphate that together may help ex

271 The ratio of ucGMP (urinary cyclic guanosine monophosphate) to BNP (B-type natriuret

272 ular guanylate cyclase domains that mobilize cyclic guanosine monophosphate upon binding of peptide.

273 The levels of nitric oxide and cyclic guanosine monophosphate were also significantly r

274 normal accumulation of the second messenger, cyclic guanosine monophosphate, which occurs in rod phot

275 ic peptide-dependent excretion of sodium and cyclic guanosine monophosphate without affecting mean ar